drugset
Drugs / Aminolevulinate
last change Oct 2025 re-read 3 minutes ago

Aminolevulinate

Developed for
actinic keratosis
Investigated by
Case Comprehensive Cancer Center · Biofrontera Inc. · National Cancer Institute (NCI) · National Institutes of Health (NIH) · The Cleveland Clinic

Trials 2

today NCT05923060 · Ph 2 NCT06027619 · Ph 2
202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT05923060 Aug 2024 → Oct 2025 actinic keratosis Case Comprehensive Cancer Center Completed No outcome recorded
Phase 2 NCT06027619 Oct 2023 → Jul 2024 actinic keratosis Case Comprehensive Cancer Center Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Aminolevulinate ClinicalTrials.gov intervention name — accepted as the source's own label NCT05923060 ↗
1

NCT06027619 ↗
Route Topical “The topical drug Levulan (ALA) will be applied to the ROI and other areas being treated” NCT05923060 ↗